RG 2133

Drug Profile

RG 2133

Alternative Names: RG2133; Triacetyluridine - Repligen; Uridine prodrug

Latest Information Update: 20 Feb 2007

Price : $50

At a glance

  • Originator Repligen
  • Developer Repligen Corporation
  • Class Antidepressants; Chemoprotectants; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metabolic disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Metabolic disorders; Mood disorders; Parkinson's disease

Most Recent Events

  • 20 Feb 2007 Discontinued - Phase-I/II for Affective disorders in USA (PO)
  • 20 Feb 2007 Discontinued - Preclinical for Parkinson's disease in USA (PO)
  • 22 Nov 2004 Preclinical trials in Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top